Elevation Oncology (ELEV) stock soars on Concentra merger agreement

Investing.com -- Shares of Elevation Oncology Inc (NASDAQ: ELEV) surged 21.2% following the announcement of a definitive merger agreement with Concentra Biosciences, LLC. Under the terms of the agreement, Concentra will acquire Elevation Oncology for $0.36 in cash per share, in addition to a non-tradeable contingent value right (CVR). The CVR entitles shareholders to potential future proceeds from the disposition of a key oncology asset, EO-1022.

The Elevation Oncology Board of Directors has unanimously approved the acquisition, deeming it in the best interests of the company's stockholders. The merger is structured such that a subsidiary of Concentra will initiate a tender offer to purchase all outstanding shares of Elevation Oncology by June 23, 2025. The transaction's completion is contingent on several conditions, including the tender of a majority of the outstanding shares and the availability of at least $26.4 million in net cash.

Approximately 5.1% of Elevation Oncology's common stock is held by officers, directors, and affiliates who have agreed to tender their shares in support of the merger. The transaction is slated for closure in July 2025, pending satisfaction of the stipulated conditions.

The merger is anticipated to bring together Elevation Oncology's expertise in developing selective cancer therapies with Concentra's resources, potentially accelerating the development of treatments for solid tumors with unmet medical needs. Fenwick & West LLP is providing legal counsel to Elevation Oncology, while Gibson, Dunn & Crutcher LLP is advising Concentra.

The stock movement reflects investor optimism about the merger's potential to unlock value for Elevation Oncology shareholders, especially considering the additional financial benefits tied to the CVR agreement. The deal highlights the ongoing consolidation in the biotech sector, as companies seek to strengthen their pipelines and enhance shareholder value through strategic acquisitions.

You May Also Be Interested In

• SATO Technologies settles senior secured debt, launches C$1.5M placement
• Vivmark Residential (VMRK) PT Lowered to $74 at BMO Capital
• Boeing wins $131B F-15 contract from Department of War